Skip to main content

Table 2 Clinicopathological characteristics of HER2-amplified PDAC

From: Clinical and molecular characterization of HER2amplified-pancreatic cancer

Patient Her2 IHC score HER2ratio HER2count Overall survival (months) Cause of death Pattern of recurrence Comments
       Lung Brain Liver Local Peritoneal  
1a 3+ 2.45 6 13.6 PDAC - ND - + + Laparotomy showed peritoneal and local recurrence
2 3+ 7.5 13 43.5 COPD - ND - - - CT at 43 months showed no recurrence
3 3+ 4.12 10 5.0 PDAC - ND - + - Local recurrence
4b 2+ 2.5 5.4 36.5 PDAC + ND - + + Ascites/pleural effusions, no liver metastases on CT
5 3+ 4.38 8.1 18.6 PDAC ND ND ND ND ND Site not documented
6 2 3.56 7 10.1 PDAC ND ND - + ND R2 resection
7 3+ 2.7 4.5 41.6 PDAC ND ND - + + No liver metastases on CT; peritoneal recurrence
8 2+ 5.32 9 10.9 PDAC + ND - + - No liver metastases on CT
9c,d 3+ 2.95 6.2 35.0 PDAC + + - - - No liver metastases on CT
10e 3+ 2.86* 6.3 27.0 PDAC + ND - - - No liver metastases on CT
  1. Abbreviations: + present; - absent; COPD chronic obstructive pulmonary disease; CT computed tomography; FISH fluorescence in situ hybridization; IHC immunohistochemistry; ND not determined; PDAC pancreatic ductal adenocarcinoma.
  2. aReceived adjuvant 5-fluouracil.
  3. bReceived adjuvant gemcitabine.
  4. cOnly case 9 received palliative chemotherapy (gemcitabine + erlotinib) and also received adjuvant gemcitabine.
  5. dCase that was whole genome sequenced.
  6. eCase 10 showed heterogeneous staining.